Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: A pharmacokinetic-pharmacodynamic modeling approach

Pharmaceutical Research

Volumn 31, Issue 10, 2014, Pages 2605-2617

  Johnson, Martin ^a   Kozielska, Magdalena ^a   Pilla Reddy, Venkatesh ^a   Vermeulen, An ^b   Barton, Hugh A ^c   Grimwood, Sarah ^c   De Greef, Rik ^d   Groothuis, Geny M M ^a   Danhof, Meindert ^e   Proost, Johannes H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c PFIZER INC   (United States)

^d NV ORGANON   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

Author keywords

catalepsy; dopamine D2< inf> receptor antagonist; EPS; Markov model; schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PYRIMIDINE DERIVATIVE; RISPERIDONE;

ANIMAL; BIOLOGICAL MODEL; BRAIN; CATALEPSY; COMPUTER SIMULATION; DOSE RESPONSE; HUMAN; METABOLISM; PROBABILITY; RAT; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CATALEPSY; COMPUTER SIMULATION; DOPAMINE D2 RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOXAZOLES; MARKOV CHAINS; MODELS, BIOLOGICAL; PYRIMIDINES; RATS; RECEPTORS, DOPAMINE D2; RISPERIDONE; SEVERITY OF ILLNESS INDEX;

EID: 84931069889     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1358-7     Document Type: Article

References (25)

1. de Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J. Dopamine D(2) occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J. 2011;13(1):121-30.
2. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, et al. High levels of dopamine D-2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996;153(7):948-50.
3. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1-dopamine and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side-effects. Arch Gen Psychiatry. 1992;49(7):538-44.
4. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double-blind pet study of schizophrenic-patients. Biol Psychiatry. 1993;33(4):227-35.
5. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409.
6. Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic-drugs with extrapyramidal side-effect liability. Psychopharmacology (Berl). 1995;120(2):128-33.
7. Wadenberg MLG, Kapur S, Soliman A, Jones C, Vaccarino F. Dopamine D-2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl). 2000;150(4):422-9.
8. Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008;83(6):909-12.
9. Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. Clin Pharmacokinet. 2007;46(5):433-47.
10. Danhof M, De Lange ECM, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008;29(4):186-91.
11. Zuideveld KP, Van der Graaf PH, Peletier LA, Danhof M. Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm Res. 2007;24(11):2031-9.
12. Bonate PL. Principles of simulation. Pharmacokinetic-pharmacodynamic modeling and simulation. Springer; 2011. p. 489.
13. Janssen PAJ, Niemegeers CJE, Schellekens KH. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part I. Neuroleptic activity spectra for rats. Arzneim Forsch. 1965;15:104-17.
14. Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D(2) receptor occupancy of olanzapine in rats. Pharm Res. 2011;28(10):2490-504.
15. Kozielska M, Johnson M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, et al. Pharmacokinetic-pharmacodynamic modeling of the D2 and 5-HT2A receptor occupancy of risperidone and paliperidone in rats. Pharm Res. 2012;29(7):1932-48.
16. Parker TJ, Della Pasqua OE, Loizillon E, Chezaubernard C, Jochemsen R, Danhof M. Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats. Br J Pharmacol. 2001;132(1):151-8.
17. Olsen CK, Brennum LT, Kreilgaard M. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol. 2008;584(2-3):318-27.
18. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21(4):457-78.
19. Ito K, Hutmacher MM, Liu J, Qiu R, Frame B, Miller R. Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder. Clin Pharmacol Ther. 2008;84(1):127-35.
20. Sheiner LB, Beal SL, Dunne A. Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. J Am Stat Assoc. 1997;92(440):1235-44.
21. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user's guides (1989-2009). Ellicott City: Icon Development Solutions; 2009.
22. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Fundation for Statistical Computing; 2009.
23. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-57.
24. Pilla Reddy V, Petersson KJ, Suleiman AA, Vermeulen A, Proost JH, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with Markov property. CPT: Pharmacometrics Syst Pharmacol. 2012;1:e1. doi: 10.1038/psp.2012.9.
25. Zingmark PH, Kagedal M, Karlsson MO. Modelling a spontaneously reported side effect by use of a Markov mixed-effects model. J Pharmacokinet Pharmacodyn. 2005;32(2):261-81.